C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib

被引：10

作者：

Tada, Toshifumi ^{[1
]}

Kumada, Takashi ^{[2
]}

Hiraoka, Atsushi ^{[3
]}

Hirooka, Masashi ^{[4
]}

Kariyama, Kazuya ^{[5
]}

Tani, Joji ^{[6
]}

Atsukawa, Masanori ^{[7
]}

Takaguchi, Koichi ^{[8
]}

Itobayashi, Ei ^{[9
]}

Fukunishi, Shinya ^{[10
]}

Tsuji, Kunihiko ^{[11
]}

Ishikawa, Toru ^{[12
]}

Tajiri, Kazuto ^{[13
]}

Ochi, Hironori ^{[14
]}

Yasuda, Satoshi ^{[15
]}

Toyoda, Hidenori ^{[15
]}

Hatanaka, Takeshi ^{[16
]}

Kakizaki, Satoru ^{[17
]}

Shimada, Noritomo ^{[18
]}

Kawata, Kazuhito ^{[19
]}

Tanaka, Takaaki ^{[3
]}

Ohama, Hideko ^{[10
]}

Nouso, Kazuhiro ^{[5
]}

Morishita, Asahiro ^{[6
]}

Tsutsui, Akemi ^{[8
]}

Nagano, Takuya ^{[8
]}

Itokawa, Norio ^{[7
]}

Okubo, Tomomi ^{[7
]}

Arai, Taeang ^{[7
]}

Imai, Michitaka ^{[12
]}

Naganuma, Atsushi ^{[20
]}

Aoki, Tomoko ^{[21
]}

Koizumi, Yohei ^{[4
]}

Nakamura, Shinichiro ^{[1
]}

Joko, Kouji ^{[14
]}

Hiasa, Yoichi ^{[4
]}

Kudo, Masatoshi ^{[21
]}

机构：

[1] Japanese Red Cross Himeji Hosp, Dept Internal Med, 1-12-1 Shimoteno, Himeji, Hyogo 6708540, Japan

[2] Gifu Kyoritsu Univ, Dept Nursing, Ogaki, Japan

[3] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Ehime, Japan

[4] Ehime Univ, Dept Gastroenterol & Metabol, Grad Sch Med, Touon, Ehime, Japan

[5] Okayama City Hosp, Dept Gastroenterol, Okayama, Japan

[6] Kagawa Univ, Dept Gastroenterol & Hepatol, Takamatsu, Kagawa, Japan

[7] Nippon Med Sch, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo, Japan

[8] Kagawa Prefectural Cent Hosp, Dept Hepatol, Takamatsu, Kagawa, Japan

[9] Asahi Gen Hosp, Dept Gastroenterol, Asahi, Japan

[10] Osaka Med Coll, Dept Gastroenterol, Osaka, Japan

[11] Teine Keijinkai Hosp, Ctr Gastroenterol, Sapporo, Hokkaido, Japan

[12] Saiseikai Niigata Hosp, Dept Gastroenterol, Niigata, Japan

[13] Toyama Univ Hosp, Dept Gastroenterol, Toyama, Japan

[14] Japanese Red Cross Matsuyama Hosp, Hepatobiliary Ctr, Matsuyama, Ehime, Japan

[15] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Ogaki, Japan

[16] Gunma Saiseikai Maebashi Hosp, Dept Gastroenterol, Maebashi, Gumma, Japan

[17] Natl Hosp Org Takasaki Gen Med Ctr, Dept Clin Res, Takasaki, Gumma, Japan

[18] Otakanomori Hosp, Div Gastroenterol & Hepatol, Kashiwa, Chiba, Japan

[19] Hamamatsu Univ Sch Med, Dept Hepatol, Hamamatsu, Shizuoka, Japan

[20] Natl Hosp Org Takasaki Gen Med Ctr, Dept Gastroenterol, Takasaki, Gumma, Japan

[21] Kindai Univ, Dept Gastroenterol & Hepatol, Osaka, Japan

来源：

SCIENTIFIC REPORTS | 2022年 / 12卷 / 01期

关键词：

LONG-TERM OUTCOMES; PROTEIN/ALBUMIN RATIO; CANCER; INFLAMMATION; SCORE; MANAGEMENT; SORAFENIB; SURGERY; IMPACT; INDEX;

D O I：

10.1038/s41598-022-12058-y

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

We investigated the impact of C-reactive protein to albumin ratio (CAR) on predicting outcomes in 522 patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib. We determined the optimal CAR cutoff value with time-dependent receiver operating characteristic curve analysis. Additionally, we clarified the relationship between CAR and liver function or HCC progression. Median overall survival was 20.0 (95% confidence interval (CI), 17.2-22.6) months. The optimal CAR cutoff value was determined to be 0.108. Multivariate analysis showed that high CAR (>= 0.108) (hazard ratio (HR), 1.915; 95% CI, 1.495-2.452), Eastern Cooperative Oncology Group performance status >= 1 (HR, 1.429), and alpha-fetoprotein >= 400 ng/mL (HR, 1.604) were independently associated with overall survival. Cumulative overall survival differed significantly between patients with low versus high CAR (p < 0.001). Median progression-free survival was 7.5 (95% CI, 6.7-8.1) months. Multivariate analysis showed that age, CAR >= 0.108 (HR, 1.644; 95% CI, 1.324-2.043), and non-hepatitis B, non-hepatitis C etiology (HR, 0.726) were independently associated with progression-free survival. Cumulative progression-free survival differed significantly between patients with low versus high CAR (p < 0.001). CAR values were significantly higher as Japan Integrated Staging score increased (p < 0.001). In conclusion, CAR can predict outcomes in patients with unresectable HCC treated with lenvatinib.

引用

页数：10

共 39 条

[1]

[Anonymous], 1989, JPN J SURG, V19, P98

[2] Management of hepatoceullular carcinoma [J].

Bruix, J ;

Sherman, M .

HEPATOLOGY, 2005, 42 (05) :1208-1236

[3] Management of Hepatocellular Carcinoma: An Update [J].

Bruix, Jordi ;

Sherman, Morris .

HEPATOLOGY, 2011, 53 (03) :1020-1022

[4] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].

Cheng, Ann-Lii ;

Kang, Yoon-Koo ;

Chen, Zhendong ;

Tsao, Chao-Jung ;

Qin, Shukui ;

Kim, Jun Suk ;

Luo, Rongcheng ;

Feng, Jifeng ;

Ye, Shenglong ;

Yang, Tsai-Sheng ;

Xu, Jianming ;

Sun, Yan ;

Liang, Houjie ;

Liu, Jiwei ;

Wang, Jiejun ;

Tak, Won Young ;

Pan, Hongming ;

Burock, Karin ;

Zou, Jessie ;

Voliotis, Dimitris ;

Guan, Zhongzhen .

LANCET ONCOLOGY, 2009, 10 (01) :25-34

[5] Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms [J].

Elinav, Eran ;

Nowarski, Roni ;

Thaiss, Christoph A. ;

Hu, Bo ;

Jin, Chengcheng ;

Flavell, Richard A. .

NATURE REVIEWS CANCER, 2013, 13 (11) :759-771

[6] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].

Finn, Richard S. ;

Qin, Shukui ;

Ikeda, Masafumi ;

Galle, Peter R. ;

Ducreux, Michel ;

Kim, Tae-You ;

Kudo, Masatoshi ;

Breder, Valeriy ;

Merle, Philippe ;

Kaseb, Ahmed O. ;

Li, Daneng ;

Verret, Wendy ;

Xu, Derek-Zhen ;

Hernandez, Sairy ;

Liu, Juan ;

Huang, Chen ;

Mulla, Sohail ;

Wang, Yulei ;

Lim, Ho Yeong ;

Zhu, Andrew X. ;

Cheng, Ann-Lii .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905

[7] The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection [J].

Haruki, Koichiro ;

Shiba, Hiroaki ;

Shirai, Yoshihiro ;

Horiuchi, Takashi ;

Iwase, Ryota ;

Fujiwara, Yuki ;

Furukawa, Kenei ;

Misawa, Takeyuki ;

Yanaga, Katsuhiko .

WORLD JOURNAL OF SURGERY, 2016, 40 (09) :2254-2260

[8] Survival model predictive accuracy and ROC curves [J].

Heagerty, PJ ;

Zheng, YY .

BIOMETRICS, 2005, 61 (01) :92-105

[9] A systematic review of the association between circulating concentrations of C reactive protein and cancer [J].

Heikkila, Katriina ;

Ebrahim, Shah ;

Lawlor, Debbie A. .

JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2007, 61 (09) :824-832

[10] AASLD guidelines for the treatment of hepatocellular carcinoma [J].

Heimbach, Julie K. ;

Kulik, Laura M. ;

Finn, Richard S. ;

Sirlin, Claude B. ;

Abecassis, Michael M. ;

Roberts, Lewis R. ;

Zhu, Andrew X. ;

Murad, M. Hassan ;

Marrero, Jorge A. .

HEPATOLOGY, 2018, 67 (01) :358-380

← 1 2 3 4 →